No Data
No Data
Have Insiders Sold Soleno Therapeutics Shares Recently?
We wouldn't blame Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders if they were a little worried about the fact that Anish Bhatnagar, the President recently netted about US$800k selling shares at
Form 144 | Soleno Therapeutics(SLNO.US) Director Proposes to Sell 506.64K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $Soleno Therapeutics(SLNO.US)$ Director Melincoff Gwen A intends to sell 12,666 shares of its common stock on Jun 28, with a total market value of approximately $506.64
Express News | Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for Dccr (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
Express News | Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | Soleno Therapeutics Inc - Set to Join Russell 3000 Index
Soleno Therapeutics Set to Join Russell 3000 Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,